Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Ayush is expanding beyond wellness to therapeutic wellness
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Combines biocompatibility, heat-resistance, transparency and durability
Subscribe To Our Newsletter & Stay Updated